FY2025 · period end Jun '25 · from the 10-K filed Aug 12, 2025
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 |
|---|---|---|---|---|
| Revenue | $222.58B |
Showing the most recent 4 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0000721371-26-000017 | Apr 30, 2026 | Apr 30, 2026 | Apr 30, 2026 10:47 UTC | EDGAR |
| 10-Q | 0000721371-26-000018 | Mar 31, 2026 | Apr 30, 2026 | Apr 30, 2026 12:51 UTC | EDGAR |
| 8-K | 0000721371-26-000013 | Mar 17, 2026 | Mar 23, 2026 | Mar 23, 2026 10:48 UTC | EDGAR |
| 8-K | 0000721371-26-000010 | Mar 2, 2026 | Mar 5, 2026 | Mar 5, 2026 12:07 UTC | EDGAR |
| 8-K | 0000721371-26-000004 | Feb 5, 2026 | Feb 5, 2026 | Feb 5, 2026 11:47 UTC | EDGAR |
| 10-Q | 0000721371-26-000006 | Dec 31, 2025 | Feb 5, 2026 | Feb 5, 2026 13:47 UTC | EDGAR |
| 8-K | 0000721371-26-000003 | Jan 13, 2026 | Jan 13, 2026 | Jan 13, 2026 11:53 UTC | EDGAR |
| 8-K | 0000721371-25-000133 | Nov 5, 2025 | Nov 6, 2025 | Nov 6, 2025 21:13 UTC | EDGAR |
Direct links to SEC EDGAR. CAH has additional filings available on the SEC site.
Figures a later SEC filing revised from what was first reported. Each diff compares the same XBRL tag across two filings — both linked, so you can check it yourself.
Operating Income (Loss)·Q1 2023
Major restatementwas-$14M
Revised down in a 10-Q.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q1 2023
Major restatementwas-$26M
Revised down in a 10-Q.
Net Income (Loss) Attributable to Parent·Q2 2022
Major restatementwas-$130M
Revised up in a 10-K.
Operating Income (Loss)·Q2 2022
Major restatementwas-$119M
Revised up in a 10-K.
Net Income (Loss) Attributable to Parent·FY 2023
Major restatementwas$261M
Revised up in a 10-K. Any P/E built on the original was 20.9% too high.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q2 2022
Major restatementwas-$137M
Revised up in a 10-K.
CAH is not the only one.
See every restatement we've found across the market — or get an alert the next time CAH revises a number.
Restatements are detected by comparing every vintage of a fact across all of CARDINAL HEALTH INC's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows CAH's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling CARDINAL HEALTH INC — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on CAH yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on CAH and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| $204.98B |
| $181.33B |
| Gross Profit | $8.17B | $7.41B | $6.87B | $6.48B |
|---|
| Operating Income | $2.27B | $1.24B | $0.75B | negative: -$0.61B |
|---|
| Net Income | $1.56B | $0.85B | $0.33B | negative: -$0.94B |
|---|
| EPS (Diluted) | $6.45 | $3.45 | $1.26 | negative: -$3.37 |
|---|
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 |
|---|---|---|---|---|
| Total Assets | $53.12B | $45.12B | $43.35B | $43.88B |
| Total Liabilities | — | — | — | — |
| Stockholders' Equity | negative: -$2.63B | negative: -$3.21B | negative: -$2.96B | negative: -$0.88B |
| Cash & Equivalents | $3.87B | $5.13B | $4.08B | $4.75B |
| Total Debt | $7.98B | $4.66B | $3.91B | $4.74B |
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 |
|---|---|---|---|---|
| Operating Cash Flow | $2.40B | $3.76B | $2.84B | $3.17B |
| Capital Expenditures | $0.55B | $0.51B | $0.48B | $0.39B |
| Free Cash Flow | $1.85B | $3.25B | $2.36B | $2.79B |
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 |
|---|---|---|---|---|
| Gross Margin | 3.7% | 3.3% | 3.4% | 3.6% |
| Operating Margin | 0.0% | 0.0% | 0.0% | negative: -0.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | negative: -0.0% |
| Return on Equity | negative: -59.3% | negative: -26.5% | negative: -11.2% | 106.3% |
| Return on Assets | 3.2% | 1.9% | 0.8% | negative: -2.1% |
| Debt / Equity | negative: -3.03× | negative: -1.45× | negative: -1.32× | negative: -5.37× |
